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A Phase II Trial of Gefitinib Monotherapy in
Chemotherapy-Naı¨ve Patients of 75 Years or Older with
Advanced Non-small Cell Lung Cancer
Noriyuki Ebi, MD,* Hiroshi Semba, MD,† Sho j i Tokunaga, PhD,‡ Koichi Takayama, MD, PhD,§
Hiroshi Wataya, MD, PhD, Takashige Kuraki, MD, PhD,¶ Hidehiko Yamamoto, MD, PhD,*
Shin j i Akamine, MD,# Isamu Okamoto, MD, PhD,** and Yoichi Nakanishi, MD, PhD§;
for the Lung Oncology Group in Kyushu, Japan
Background: Gefitinib has shown modest activity in patients with
recurrent non-small cell lung cancer (NSCLC) after platinum-based
chemotherapy. However, the activity of gefitinib as first-line che-
motherapy remains unclear, especially unknown in elderly patients.
A multicenter phase II trial was conducted to evaluate the efficacy
and tolerability of gefitinib for elderly patients with chemotherapy-
naı¨ve NSCLC.
Methods: Elderly chemotherapy-naı¨ve patients with advanced
NSCLC, ECOG PS of 0–2, and adequate organ functions received
250 mg/day of gefitinib. The primary objective of this study was to
determine the objective response rate (RR). Secondary endpoints
were tolerability, disease-related symptom using lung cancer sub-
scale (LCS) in FACT-L, progression free survival (PFS) and overall
survival (OS). We investigated mutation status of the epidermal
growth factor receptor (EGFR) gene in cases with available tumor
samples.
Results: Fifty patients were enrolled, of whom 49 were eligible.
Median age (range) was 80 (75–90) years. Thirty-two patients were
female (65%) and 40 patients had adenocarcinoma (82%). The
objective RR was 25% (CI 95%, 13–39). Median survival time was
10 months (CI 95%, 7–20) and 1-year survival rate was 50%. The
most frequent adverse events were skin disorders (76%). Fifteen
patients (30%) experienced toxicities grade 3. There were four
patients with possible interstitial lung disease including two treat-
ment-related deaths. Symptom improvement rate using LCS was
49% at 4 weeks of gefitinib therapy. Tumor samples from 17
patients were analyzed for EGFR mutation status. EGFR mutations
were detected in tumor tissues from 7 patients, of which 5 had partial
responses (71%).
Conclusions: Gefitinib monotherapy is effective and relatively well
tolerated in chemotherapy-naı¨ve elderly patients with advanced
NSCLC. Gefitinib has potential as a first-line therapeutic option in
elderly patients with advanced NSCLC.
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The incidence of lung cancer, the major cause of cancer-related mortality worldwide, increases with age.1 More
than 30% of lung cancer patients are diagnosed at an age
of 75 years,2 and this proportion is likely to increase over
the coming years. Approximately 80 to 85% of lung cancer
subtypes are of non-small cell histology. In patients with
advanced non-small cell lung cancer (NSCLC) chemother-
apy improves survival, disease-related symptoms, and
quality of life (QoL) compared with best supportive care3
and combination chemotherapy involving newer agents is
now considered the standard first-line treatment for most
patients with advanced NSCLC.4,5 However, combination
chemotherapy causes increased hematologic and neuropsy-
chiatric toxicity in older patients,6,7 and 90% of elderly
patients experience a grade 3 toxicity when treated with
a platinum-based doublet.8 Therefore, single-agent chemo-
therapy is considered as a standard treatment for elderly
patients with advanced NSCLC.9,10 An effective, less toxic
therapy might help extend potentially beneficial treatment
to a greater proportion of older patients who would other-
wise be considered unsuitable for chemotherapy. Recently,
molecular-targeted agents have been introduced for the
treatment of NSCLC. Gefitinib, an orally active epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI), is a leading agent in the field of EGFR-targeted
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therapy.11 In two international, randomized phase II trials
(Iressa Dose Evaluation in Advanced Lung cancer [IDEAL]-1
and IDEAL-2) in patients with advanced or metastatic NSCLC
after platinum-based chemotherapy, treatment with gefitinib
250 mg monotherapy resulted in response rates (RRs) of 12
to 18%, good tolerability and symptom improvement.12,13
The subset analyses in both trials revealed no significant
difference in terms of the RR and adverse events (AEs)
reported with gefitinib between younger and older patients.
Despite the high incidence of NSCLC and its high mortality
rate in elderly patients,1 the likelihood of receiving systemic
chemotherapy seems to decrease with increasing age—in par-
ticular, the age of75 years—due to the progressive decline in
organ function, and age-related comorbidities. Therefore, we
conducted a phase II study of gefitinib monotherapy in chemo-
therapy-naive patients75 years of age with advanced NSCLC.
PATIENTS AND METHODS
Patient Population
Patients with histologically or cytologically confirmed
NSCLC that was inoperable as a result of substantial comor-
bidity, impairment of respiratory function or anatomic con-
traindication were eligible. Patients were to be aged 75 years
or older, and to have an Eastern Co-operative Oncology
Group Performance Status 0 to 2, measurable disease, PaO2
60 mmHg and adequate organ function. Exclusion criteria
were: prior chemotherapy or thoracic radiotherapy; interstitial
pneumonia or pulmonary fibrosis; as determined by chest
computed tomography (CT); paralytic ileus or vomiting; symp-
tomatic brain metastases; active infection; active concomitant
malignancy; pregnancy or breast-feeding; and severe allergy to
study drugs. All patients gave written informed consent before
enrolment. This protocol was approved by the Institutional
Review Boards of the participating centers.
Treatment Plan
Baseline assessment included a medical history and phys-
ical examination, standard laboratory studies, ECG, CT of the
chest and abdomen, head CT or magnetic resonance imaging,
and disease-related symptoms using lung cancer subscale (LCS)
in The Functional Assessment of Cancer Therapy–Lung.14 Pa-
tients were treated with gefitinib 250 mg daily until disease
progression, severe or intolerable toxicity, or withdrawal of
consent.
Patients were evaluated for objective response every
month using Response Evaluation Criteria in Solid Tumors
guidelines.15 The objective response was evaluated centrally
by an independent review board. All AEs reported during
gefitinib treatment were recorded and severity was graded
according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 2.0.16 Treatment
interruptions up to 14 days were allowed for toxicities
grade 3, and patients were restarted if toxicities recovered
to grade 2 within 14 days.
Disease-Related Symptom Analysis
Disease-related symptoms were assessed by LCS before
therapy and at 1, 2, and 4 weeks. Symptom improvement was
defined as a 2-point or greater increase in score on the summed
LCS.17
Mutation Analysis of the EGFR Gene
Tumor specimens (paraffin embedded) were collected
from previous diagnostic or surgical procedures. DNA was
extracted from tumor tissues derived either by macrodissec-
tion or by laser-capture microdissection performed to enrich
tumor cells, using the QIAamp Micro kits (QIAGEN KK,
Tokyo, Japan). The amplification-refractory mutation system
(ARMS) with designed “scorpion” primers were applied for the
allele-specific detection of EGFR mutations.18 Only the follow-
ing mutations described in previous studies were classified as
mutations in the present study: G719X in exon 18, deletion of
E746 to A750 or of neighboring residues in exon 19, and L858R
and L861Q in exon 21. All mutations were confirmed by
analysis of at least two independent amplification products.
Statistical Analysis
This study was a multicenter, single-arm, noncomparative
phase II clinical trial. The primary end point was objective RR.
Secondary endpoints were tolerability, disease-related symp-
toms using LCS in Functional Assessment of Cancer Therapy–
Lung, progression free survival (PFS) and overall survival (OS).
With the target activity level of 30% and the lowest RR of
interest set at 15%, 48 patients were required with   0.048
and   0.18 assuming binomial distribution of RR. Allowing
for a loss, a total of 50 patients were planned to enroll. All
eligible patients were included in the analysis of response. The
95% confidence interval (CI) of the RR was calculated by the
exact method, assuming a binomial distribution of data. PFS was
defined as the time from registration until objective tumor
progression or death. Patients whose disease had not progressed
at the time of discontinuation of the study treatment continued to
be assessed until progression was documented. If a patient died
without documentation of disease progression, the patient was
considered to have had tumor progression at the time of death,
unless there was sufficient documented evidence to conclude
otherwise. PFS and OS were estimated using the Kaplan-Meier
method.19 To examine the association of tumor response to
gefinitib and OS with clinical factors including EGFR muta-
tions, two-sided Fisher’s exact test and Log-rank test, respec-
tively, were used. To examine the time tendency of disease
related symptoms, Generalized Estimation Equation model was
used.20 The model includes the repeated measured LCS as a
continuous dependent variable and time in week as a continuous
explanatory variable. A two-sided p  0.05 was considered
statistically significant.
RESULTS
Patients and Treatment Administration
Fifty patients were enrolled between April 2004 and
May 2006 at 22 centers across Kyushu in Japan. Of these, 49
patients were deemed eligible (one stage IB patient with no
indications for surgery or curative radiotherapy due to severe
emphysema). One patient was ineligible because of stage
IIIA with an indication for curative radiotherapy. Patient
characteristics are listed in Table 1. Median age (range) was
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80 (75–90) years. Thirty-two patients were female (65%) and
12 patients (24%) had a performance status (PS) of 2. The
most common histologic NSCLC subtype was adenocarci-
noma (82%). Most patients (82%) had stage IV disease or
recurrence after surgical resection and 30 patients were never
smokers (61%). Of the 49 patients, 46 patients discontinued
gefitinib treatment by reason of progression of disease (n 
31), treatment-related AEs (n  13), patient request (n  1),
and another disease (n  1). The median treatment period
was 2.8 months (range: 0.1–16 months). Three patients are
still receiving treatment with gefitinib.
Adverse Events
Table 2 lists the AEs by grade. The most frequent AEs
were skin disorders (76%) including rash, dry skin, pruritus,
acne, and nail changes. In general, toxicities were mild (grade
1–2) and easily managed. Fifteen patients (30%) experienced
toxicities grade 3. Thirteen were withdrawn from the study
because of treatment-related AEs–four patients with intersti-
tial lung disease (ILD), four with rash, one with asthenia, one
with diarrhea, one with mucositis, one with hypoxemia, and
one with hepatic toxicity. There were four patients with
possible ILD including two treatment-related deaths.
Response
There were 12 partial responses (PRs) among the 49
patients, yielding an overall RR of 25% (95% CI, 13–39%).
Seventeen patients (35%) achieved stable diseases (SDs) and
the overall disease control rate (PR SD) was 59% (95% CI,
44–73%). Four patients were removed from the study before
being evaluated for response; two patients had ILD, one had
a stroke, and one had deteriorated PS. (Table 3).
PFS and Survival
All 49 eligible patients were assessed for PFS and
survival. At the time of analysis, there were 31 deaths, 17
patients confirmed alive, and one patient lost to follow-up.
Median survival time was 10 months (95% CI, 7–20; Figure
1A). Median PFS was 4 months (95% CI, 3–8; Figure 1B).
The 1- and 2-year survival rates were 50% and 23%, respec-
tively.
Disease-Related Symptoms
With respect to disease-related symptoms, the mean
LCS scores were 21, 22, 22, and 23 points before the therapy
and at 1, 2, and 4 weeks, respectively. The time tendency of
change in LCS scores was significant (p  0.017) (Table 4).
There was no significant association between response and
symptom improvement (Table 5).
TABLE 1. Patient Characteristics
Characteristics No. of Patients %
Patients enrolled 50
Patients eligible 49
Age
Median 80
Range 75–90
Sex
Male 17 35
Female 32 65
Performance status
0 13 27
1 24 49
2 12 24
Stage at enrolment
IBa 1 2
IIIB 8 16
IV 40 82
Histology
Adenocarcinoma 40 82
Squamous cell carcinoma 6 12
Large cell carcinoma 0 0
Other 3 6
Smoking status
Never 30 61
Former 16 33
Current 3 6
a No indications for surgery or curative radiotherapy due to severe emphysema.
TABLE 2. Common Adverse Events (n  50)
Toxicity
All Grade 3–5a
No. % No. %
Dermalb 38 76 10 20
Anaemia 33 66 3 6
Anorexia 25 50 6 12
Fatigue 21 42 5 10
Hepatic 20 40 11 22
Diarrhoea 14 28 2 4
Nausea 11 22 1 2
Neutropenia 11 22 0 0
Renal 11 22 0 0
Mucositis 7 14 1 2
ILD 4 8 3 6
Vomiting 3 6 0 0
a Two patients experienced grade 5 events related to gefitinib-induced ILD.
b Dermal toxicities including rash, dry skin, pruritus, acne and nail changes.
ILD, interstitial lung disease.
TABLE 3. Best Overall Objective Response (n  49)
Type of Response
No. of
Patients
% of
Patients
Complete response 0 0
Partial response 12 25
Stable disease 17 35
Progressive disease 16 33
Not evaluablea 4 8
Overall response (CI 95%) 12 25 (13–39)
a Four patients were removed from study before being evaluated for response; two
patients had interstitial lung disease (ILD), one had stroke and one had deteriorated
performance status (PS).
CI 95%, 95% confidence interval.
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Mutation Analysis of the EGFR Gene
Tumor samples from 17 patients were analyzed for
EGFR mutations by Scorpion-ARMS. EGFR mutations, con-
sisting of in-frame deletions in exon 19 (n  2) and point
mutations in exon 21 (n 5) were detected in 7 tumor tissues
(41%). All patients harboring EGFR mutations achieved
either PRs or SDs. Five patients with EGFR mutations had
PRs and the RR was 71%. Of the 10 patients without EGFR
mutations (59%), 2 patients had PRs, 3 had SDs and 5 had
progressive diseases. The presence of EGFR mutations was
associated with prolonged survival in this trial (Table 5).
Second-Line Chemotherapy
Thirteen patients received second-line chemotherapy
(gefitinib rechallenge, n  5; docetaxel monotherapy, n  4;
gemcitabine plus tegafur-uracil, n  2; gemcitabine plus
vinorelbine, n  1; or gemcitabine monotherapy, n  1).
Altogether, two patients partially responded to second-line
gemcitabine plus tegafur-uracil, or gemcitabine monotherapy,
with no responses among patients receiving other regimens.
Overall RR to second-line chemotherapy was 15%.
DISCUSSION
Given the increasing number of elderly individuals with
advanced NSCLC, it is important for clinicians to be ready to
manage these challenging patients in the coming decades.
Prospective randomized trials in elderly (70 years or older)
TABLE 4. Disease-Related Symptoms Evaluated by Lung
Cancer Subscale
Before Therapy
n  42
After 1 wk
n  41
After 2 wk
n  39
After 4 wk
n  35
Mean LCS score 21 22 22 23
Change of LCS Score from Baseline No. of Patients (%)
2 Improved 15 (37) 14 (36) 17 (49)
2 Worsened 5 (12) 10 (26) 8 (23)
Otherwise No change 21 (51) 15 (39) 10 (29)
The time trend in repeated measured LCS was statistically significant (p  0.017)
according to Generalized Estimation Equation model analysis.
LCS, lung cancer subscale.
FIGURE 1. A, overall survival (OS) and (B) pro-
gression-free survival (PFS) of all eligible patients
(n  49). Median OS was 10 months. Median PFS
was 4 months.
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advanced NSCLC patients are now available. The Elderly
Lung Cancer Vinorelbine Italian Study Group reported sig-
nificantly superior survival and QoL with single-agent vi-
norelbine over best supportive care.9 The conclusive results
were reported in other Multicenter Italian Lung Cancer in the
Elderly Study, which enrolled more than 700 patients and
reported no significant survival difference between single-
agent vinorelbine, single-agent gemcitabine, or a regimen
with both agents combined.10 These studies together provide
evidence that single-agent chemotherapy is considered as a
standard treatment for advanced NSCLC elderly patients.
The present phase II study was designed to evaluate the
efficacy and tolerability of single agent treatment with ge-
fitinib in previously untreated NSCLC patients 75 years of
age. The observed RR of 25% (95% CI, 13–39%), median
PFS of 4 months, median survival of 10 months and 1-year
survival rate of 50% are promising in elderly advanced
NSCLC. One potential limitation in interpreting efficacy data
from this trial is a possible selection bias on the part of
treating physicians. Although this study planned to recruit
unselected patients, a higher percentage of women (65%),
never smokers (61%), and patients with adenocarcinoma
(82%) were enrolled. This was a result of the growing
evidence that these clinical characteristics are more often
associated with benefit from EGFR-TKIs.12,13,21 A random-
ized phase II study (median age 70) comparing combina-
tion chemotherapy with another EGFR-TKI, erlotinib for
chemotherapy-naive advanced NSCLC patients with a PS of
2 (who accounted for 24% of our study enrollment) showed
a superior response rate, PFS and OS in combination chemo-
therapy relative to erlotinib. However, subgroup analyses
revealed a longer PFS in erlotinib relative to combination
chemotherapy for women, never smokers, and patients with
adenocarcinoma.22 Indeed, our subgroup analyses demon-
strated that all responders in the present study were women,
and never smokers had a higher response rate than smokers
(37 versus 5%). Imbalance of responders by gender may be
attributed to the fact that most women enrolled in this study
were never smokers. On the other hand, histologic subtype as
another predicting factor did not show any significant differ-
ences in response rate, possibly due to the small sample size.
The recent discovery of somatic mutations in the ty-
rosine kinase domain of EGFR and of the association of such
mutations with a high response rate to EGFR-TKIs has had a
profound impact on the treatment of advanced NSCLC.23–25
In the present study, we used Scorpion-ARMS which is more
sensitive than direct sequencing for detection of the known
EGFR mutations that reflect responsiveness to EGFR-TKIs.18
Our analyses demonstrated that EGFR mutations were de-
tected in 7 of 17 patients (41%), and those 5 patients achieved
PRs and 2 patients had SDs. It is noteworthy that the presence
of EGFR mutations was associated with longer survival
(median 27 months), although it remains unclear whether
EGFR mutations are predictive of EGFR-TKIs treatment
benefit or merely prognostic of prolonged survival. Disease-
related symptom improvement may be more important fac-
tors than tumor response and survival in the treatment of
elderly patients with advanced NSCLC. In the present study,
LCS revealed a significant symptom improvement from the
start of gefitinib therapy to 4 weeks. Symptom improvement
rate was 49% at 4 weeks of gefitinib therapy, which compares
favorably with the improvement rate reported for the overall
population in IDEAL-2 (39%).17
The toxicity of gefitinib in this study compares favor-
ably with other studies performed in patients with NSCLC
older than age 70 years. Fifteen patients (30%) experienced
toxicitiesgrade 3. The most frequent AEs (G3) were skin
disorders and hepatic dysfunction. There were four patients
with possible ILD including two treatment-related deaths.
Gefitinib-induced ILD in the Japanese patients, of
which multivariate analysis identified male sex, a history of
smoking, and coincidence of interstitial pneumonia as signif-
icant risk factors, revealed a higher incidence of 3.2%, rang-
ing from 0.4% in female never-smokers to 6.6% in male
smokers, than in other ethnicities.21 Despite strict exclusion
of interstitial pneumonia by chest CT, there were 4 patients
with possible ILD (8%) in the present study, including 2
treatment-related deaths (4%). One patient with treatment-
related death was a male smoker with the higher risk of
gefitinib-induced ILD, however, another was a female never-
smoker with the lower risk. With strict exclusion of intersti-
tial pneumonia by chest CT, it might be difficult to com-
pletely prevent development of gefitinib-induced ILD as it
was previously reported that 5 of 34 patients without inter-
stitial shadow by chest CT experienced ILD.26 Further sci-
entific investigations are required to elucidate gefitinib-
induced ILD.
A recent phase III study for elderly patients (70) with
advanced NSCLC (WJTOG9904) reported that docetaxel
monotherapy significantly improved RR, PFS, and overall
disease-related symptoms compared with vinorelbine mono-
TABLE 5. Association of Tumor Response to Gefitinib and
Median Overall Survival with Clinicopathological Factors
Characteristics
(no. of patients)
ORR MS
% P1 mo P2
Gender
Male (17) 0 0.01 8 0.12
Female (32) 38 17
Histology
Adeno ca. (40) 28 0.42 13 0.06
Nonadeno ca. (9) 11 4
Smoking
Never (30) 37 0.02 17 0.10
Current/Former (19) 5 8
LCS score
Improved/No change (27)a 33 0.39 17 0.43
Worsened (8)a 13 6
EGFR mutation
Positive (7) 71 0.06 27b 0.01
Negative (10) 20 7
a This is at 4 wk of therapy.
b MS has not yet been reached.
ORR, objective response rate; MS, median survival; P1, two-sided P for difference
in ORR; P2, two-sided P for difference in overall survival; LCS, lung cancer subscale.
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therapy.27 The data suggest that docetaxel monotherapy
should be considered as an option in the standard treatment in
this patient population. More recently, a large second line
trial comparing gefitinib with docetaxel (INTEREST trial n
1440) demonstrated the noninferiority of gefitinib to do-
cetaxel in terms of OS, with a more favorable toxicity profile
and QoL score in gefitinib arm.28 These findings support the
notion that EGFR-TKIs may be an ideal agent to investigate
in the first line setting in elderly patients with advanced
NSCLC. It has been recently reported that another EGFR-
TKIs, erlotinib, is active and relatively well tolerated in
chemotherapy-naive elderly patients (70) with advanced
NSCLC.29
In conclusion, we showed the effective outcome of
gefitinib monotherapy in chemotherapy-naive patients 75
years of age with advanced NSCLC. Despite our intentions
not to discriminate, a higher percentage of women (65%),
never smokers (61%), and patients with adenocarcinoma
(82%) were enrolled because of a possible selection bias on
the part of treating physicians. Although our present study
suggests that gefitinib is a viable option for such selected
patients, our data may not be applicable to elderly patients in
general. Further studies are required to determine which
patients will ultimately benefit from this therapy.
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